LFG
KRYS icon

Larson Financial Group’s Krystal Biotech KRYS Stock Holding History

Larson Financial Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.13K Sell
16
-1
-6% -$266 ﹤0.01% 2685
2025
Q4 		$4.19K Hold
17
– – ﹤0.01% 2525
2025
Q3 		$3K Buy
17
+15
+750% +$2.25K ﹤0.01% 2542
2025
Q2 		$275 Buy
+2
New +$294 ﹤0.01% 2996

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Larson Financial Group's KRYS Position: Q1 2026 in Review

Larson Financial Group reduced its Krystal Biotech (KRYS) stake by 5.9% in Q1 2026, selling an estimated $266 and leaving 16 shares worth $4.13K. The position accounts for ﹤0.01% of the portfolio, ranked #2685.

Larson Financial Group first reported a position in KRYS in Q2 2025 and has held it in 4 quarters since. The position peaked at $4.19K in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Larson Financial Group held 16 shares of Krystal Biotech worth $4.13K as of Q1 2026.
  • Larson Financial Group sold 1 Krystal Biotech share in Q1 2026, an estimated $266.
  • Krystal Biotech made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #2685 holding.
  • Larson Financial Group first reported a position in Krystal Biotech in Q2 2025 and has held it in 4 quarters since.
  • Larson Financial Group's Krystal Biotech position peaked at $4.19K in Q4 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.